🍪 The GLP Lounge uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsPharmacology & MechanismsGLP-1/GIP receptor co-agonism — anyone have experience? Page 2

GLP-1/GIP receptor co-agonism — anyone have experience?

Dr.NephBHM_UK Thu, Apr 2, 2026 at 2:36 AM 36 replies 1,378 viewsPage 2 of 8
BenResearch_OR
Senior Member
2,456
11,234
Dec 2023
Oregon
Apr 2, 2026 at 7:25 AM#6
KevinCompounds said:
Steady state is faster than people expect: half-life about five days, so you are at plateau in roughly three to four weeks rather than five.

This is where I part company with the consensus forming above. The "tirzepatide is simply better" summary irritates me. It is better on mean weight loss, and the cardiovascular outcome evidence is far thinner than semaglutide's. If the reason for treating is cardiovascular risk rather than weight, the evidence base points the other way.

Ask again with the specifics and you will get a better answer than this one.

Last edited: Apr 2, 2026 at 8:25 AM
48 18julia.endo, JessicaM_2024, TomFromTexas and 45 others
Reply Quote Save Share Report
VendorMark
Senior Member
3,456
14,567
Jan 2024
Texas
Online
Apr 2, 2026 at 9:18 AM#7

Adding the numbers, since they settle part of this. Numbers worth memorising for this class: Tmax one to three days for the weekly peptides, terminal half-life about a week for semaglutide and about five days for tirzepatide, steady state at four to five half-lives, subcutaneous bioavailability high enough that site choice is irrelevant.

Last edited: Apr 2, 2026 at 11:18 AM
47 17KristenIndy, MarkLI_maint, Dr.PeteFamMed and 44 others
Reply Quote Save Share Report
Dr.ReproEndo
Senior Member
1,890
8,901
Jan 2024
Scottsdale, AZ
Apr 2, 2026 at 11:11 AM#8
BenResearch_OR said:
The "tirzepatide is simply better" summary irritates me.

Adding the part of the answer the thread has not reached. The mechanism is more central than most summaries suggest. Receptor agonism in the arcuate nucleus activates POMC neurons and inhibits AgRP/NPY signalling, and the downstream MC4R pathway is the same one disrupted in monogenic obesity — convergent genetic evidence that the target is the right one. Peripherally there is glucose-dependent insulin secretion, glucagon suppression and delayed gastric emptying, but the gastric component largely adapts over months while the central effect persists, which is why the durable effect is appetite rather than fullness.

46 16Dr.EndoEP, GraceAZ_72, carl_compliance and 43 others
Reply Quote Save Share Report

PeptideMeter — Independent Peptide Analytics

Community-driven peptide testing and vendor rating platform. Transparent results. Unbiased analysis. Trusted by thousands.

View Results
SleepDoc_PDX
Member
289
1,234
Sep 2024
Portland, OR
Apr 2, 2026 at 1:04 PM#9

A narrower follow-up, since the general answer is now clear:

How much of the tirzepatide advantage is the GIP component and how much is simply that the dose ladder goes higher in receptor-occupancy terms?

Last edited: Apr 2, 2026 at 4:04 PM
45 15sophie_paris, mel_PDX, Dr.AddMedPHL and 42 others
Reply Quote Save Share Report
Dr.NephBHM_UK
Member
456
2,123
Jun 2024
Birmingham, UK
Apr 2, 2026 at 10:04 PM#10

OP back with an update, since a thread like this is useless without one.

Update: the eight-week restart pattern people described is exactly what happened. I nearly abandoned it at week five.

43 18PeptideChemSF, A1cHero_PHX, Dr.RenalNash and 40 others
Reply Quote Save Share Report

Similar Threads

GLP-1R desensitization — β-arrestin-mediated internalization18 replies
Biased agonism at GLP-1R — Gs vs β-arrestin signaling balance13 replies
Semaglutide albumin binding and the C-18 fatty acid linker17 replies
GIP receptor pharmacology — why GIP agonism enhances GLP-113 replies
Glucagon receptor signaling — hepatic glycogenolysis and lipolysis16 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register